Loading...

Bota, Daniela A

TitleAssociate Professor
InstitutionUniversity of California, Irvine
DepartmentNeurology
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-7214
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Mechanisms of Chemotherapy Induced Cognitive Defects
    NIH/NINDS K08NS072234Aug 15, 2011 - Mar 31, 2016
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Bota DA, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FP, Schönthal AH, Hofman FM, Chen TC, Zidovetzki R, Pretto C, Strik A, Schijns VE, Stathopoulos A. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts. CNS Oncol. 2018 Aug 29. PMID: 30157683.
      View in: PubMed
    2. Schijns VEJC, Pretto C, Strik AM, Gloudemans-Rijkers R, Deviller L, Pierre D, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FPK, Hofman FM, Chen TC, Zidovetzki R, Bota DA, Stathopoulos A. Therapeutic Immunization against Glioblastoma. Int J Mol Sci. 2018 Aug 27; 19(9). PMID: 30150597.
      View in: PubMed
    3. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 Jun 29; 16(1):179. PMID: 29958537.
      View in: PubMed
    4. Jamieson CHM, Millan MT, Creasey AA, Lomax G, Donohoe ME, Walters MC, Abedi M, Bota DA, Zaia JA, Adams JS. CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine Challenges. Cell Stem Cell. 2018 Jun 01; 22(6):801-805. PMID: 29859170.
      View in: PubMed
    5. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walpert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 May 29; 16(1):142. PMID: 29843811.
      View in: PubMed
    6. Pham JT, Kim RC, Nguyen A, Bota D, Kong XT, Vadera S, Hsu F, Carrillo JA. Intracranial meningioma with carcinoma tumor-to-tumor metastasis: two case reports. CNS Oncol. 2018 Apr; 7(2):CNS09. PMID: 29698064.
      View in: PubMed
    7. Shaterian A, Bota D, Leis A. Expression of the BRAF L597Q mutation in sporadic neurofibromas of the upper extremity. Exp Mol Pathol. 2017 12; 103(3):276-278. PMID: 29162506.
      View in: PubMed
    8. Lomeli N, Bota DA, Davies KJA. Diminished stress resistance and defective adaptive homeostasis in age-related diseases. Clin Sci (Lond). 2017 Nov 01; 131(21):2573-2599. PMID: 29070521.
      View in: PubMed
    9. Chow D, Chang P, Weinberg BD, Bota DA, Grinband J, Filippi CG. Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions. AJR Am J Roentgenol. 2018 Jan; 210(1):30-38. PMID: 28981352.
      View in: PubMed
    10. Yan H, Romero-López M, Benitez LI, Di K, Frieboes HB, Hughes CCW, Bota DA, Lowengrub JS. 3D Mathematical Modeling of Glioblastoma Suggests That Transdifferentiated Vascular Endothelial Cells Mediate Resistance to Current Standard-of-Care Therapy. Cancer Res. 2017 08 01; 77(15):4171-4184. PMID: 28536277.
      View in: PubMed
    11. Nolen SC, Evans MA, Fischer A, Corrada MM, Kawas CH, Bota DA. Cancer-Incidence, prevalence and mortality in the oldest-old. A comprehensive review. Mech Ageing Dev. 2017 06; 164:113-126. PMID: 28502820.
      View in: PubMed
    12. Majd P, O'Connell DE, Kim RC, Bota DA, Carrillo JA. Case of glioblastoma patient treated with tumor treating fields therapy at recurrence degenerating to sarcoma. CNS Oncol. 2017 Apr; 6(2):89-94. PMID: 28303729.
      View in: PubMed
    13. O'Connell D, Shen V, Loudon W, Bota DA. First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report. CNS Oncol. 2017 01; 6(1):11-18. PMID: 27918194.
      View in: PubMed
    14. Lomeli N, Di K, Czerniawski J, Guzowski JF, Bota DA. Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. Free Radic Biol Med. 2017 01; 102:274-286. PMID: 27908784.
      View in: PubMed
    15. Di K, Lomeli N, Wood SD, Vanderwal CD, Bota DA. Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma. Oncotarget. 2016 Nov 22; 7(47):77457-77467. PMID: 27764809.
      View in: PubMed
    16. John T, Lomeli N, Bota DA. Systemic cisplatin exposure during infancy and adolescence causes impaired cognitive function in adulthood. Behav Brain Res. 2017 02 15; 319:200-206. PMID: 27851909.
      View in: PubMed
    17. Trusheim J, Dunbar E, Battiste J, Iwamoto F, Mohile N, Damek D, Bota DA, Connelly J. A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. CNS Oncol. 2017 01; 6(1):29-43. PMID: 27628854.
      View in: PubMed
    18. Nolen SC, Lee B, Shantharam S, Yu HJ, Su L, Billimek J, Bota DA. The effects of sequential treatments on hippocampal volumes in malignant glioma patients. J Neurooncol. 2016 09; 129(3):433-441. PMID: 27393350.
      View in: PubMed
    19. Bota DA, Davies KJ. Mitochondrial Lon protease in human disease and aging: Including an etiologic classification of Lon-related diseases and disorders. Free Radic Biol Med. 2016 11; 100:188-198. PMID: 27387767.
      View in: PubMed
    20. John TD, Sender LS, Bota DA. Cognitive Impairment in Survivors of Adolescent and Early Young Adult Onset Non-CNS Cancers: Does Chemotherapy Play a Role? J Adolesc Young Adult Oncol. 2016 Sep; 5(3):226-31. PMID: 27078009.
      View in: PubMed
    21. Di K, Lloyd GK, Abraham V, MacLaren A, Burrows FJ, Desjardins A, Trikha M, Bota DA. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neuro Oncol. 2016 06; 18(6):840-8. PMID: 26681765; PMCID: PMC4864261 [Available on 06/01/17].
    22. Schijns VE, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC, Mespouille P, Hantos P, Glorieux P, Bota DA, Stathopoulos A. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine. 2015 May 28; 33(23):2690-6. PMID: 25865468.
      View in: PubMed
    23. Bota DA, Alexandru-Abrams D, Pretto C, Hofman FM, Chen TC, Fu B, Carrillo JA, Schijns VE, Stathopoulos A. Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. Perm J. 2015; 19(2):41-6. PMID: 25785641; PMCID: PMC4403580.
    24. Abrams DA, Hanson JA, Brown JM, Hsu FP, Delashaw JB, Bota DA. Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma. J Clin Neurosci. 2015 Jan; 22(1):35-9. PMID: 25481268.
      View in: PubMed
    25. Di K, Keir ST, Alexandru-Abrams D, Gong X, Nguyen H, Friedman HS, Bota DA. Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models. J Neurooncol. 2014 Dec; 120(3):473-81. PMID: 25115740.
      View in: PubMed
    26. Andres AL, Gong X, Di K, Bota DA. Low-doses of cisplatin injure hippocampal synapses: a mechanism for 'chemo' brain? Exp Neurol. 2014 May; 255:137-44. PMID: 24594220; PMCID: PMC4059602.
    27. Novac AA, Bota D, Witkowski J, Lipiz J, Bota RG. Special medical conditions associated with catatonia in the internal medicine setting: hyponatremia-inducing psychosis and subsequent catatonia. Perm J. 2014; 18(3):78-81. PMID: 25102520; PMCID: PMC4116269.
    28. Paff M, Alexandru-Abrams D, Hsu FP, Bota DA. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients. Hum Vaccin Immunother. 2014; 10(11):3322-31. PMID: 25625931; PMCID: PMC4514075.
    29. Alexandru-Abrams D, Jadus MR, Hsu FP, Stathopoulos A, Bota DA. Therapeutic targeting of malignant glioma. Anticancer Agents Med Chem. 2014; 14(8):1075-84. PMID: 25175690.
      View in: PubMed
    30. Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. J Neurosurg. 2013 Dec; 119(6):1415-23. PMID: 24093630; PMCID: PMC4550014.
    31. Fu DB, Alexandru D, Curticiu DM, Fu Y, Bota DA. Two Patients With Brain Tumors Who Received Bevacizumab and Radiotherapy: Optic Neuropathy and Quality-of-Life Issues. J Adv Pract Oncol. 2013 Jul; 4(4):252-6. PMID: 25032005; PMCID: PMC4093434.
    32. Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Lee JW, Kesari S. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. J Neurosurg. 2013 Jun; 118(6):1183-7. PMID: 23451905.
      View in: PubMed
    33. Hanson JA, Hsu FP, Jacob AT, Bota DA, Alexandru D. Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme. Perm J. 2013; 17(4):68-74. PMID: 24361023; PMCID: PMC3854812.
    34. Ge L, Hoa NT, Cornforth AN, Bota DA, Mai A, Kim DI, Chiou SK, Hickey MJ, Kruse CA, Jadus MR. Glioma big potassium channel expression in human cancers and possible T cell epitopes for their immunotherapy. J Immunol. 2012 Sep 01; 189(5):2625-34. PMID: 22844111; PMCID: PMC3496203.
    35. Alexandru D, Bota DA, Linskey ME. Epidemiology of central nervous system metastases. Prog Neurol Surg. 2012; 25:13-29. PMID: 22236665.
      View in: PubMed
    36. Chamberlain MC, Bota DA, Linskey ME, Schwartz PH. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology. 2011 Nov 29; 77(22):e135; author reply e135-6. PMID: 22123788.
      View in: PubMed
    37. Ngo JK, Pomatto LC, Bota DA, Koop AL, Davies KJ. Impairment of lon-induced protection against the accumulation of oxidized proteins in senescent wi-38 fibroblasts. J Gerontol A Biol Sci Med Sci. 2011 Nov; 66(11):1178-85. PMID: 21868393; PMCID: PMC3193527.
    38. Alexandru D, Glantz MJ, Kim L, Chamberlain MC, Bota DA. Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by ¹¹¹Indium-octreotide imaging. Cancer. 2011 Oct 01; 117(19):4506-11. PMID: 21446045.
      View in: PubMed
    39. Ge L, Hoa N, Bota DA, Natividad J, Howat A, Jadus MR. Immunotherapy of brain cancers: the past, the present, and future directions. Clin Dev Immunol. 2010; 2010:296453. PMID: 21437175; PMCID: PMC3061456.
    40. Mathews MS, Bota DA, Kim RC, Hasso AN, Linskey ME. Primary leptomeningeal plasmablastic lymphoma. J Neurooncol. 2011 Sep; 104(3):835-8. PMID: 21359853; PMCID: PMC3171045.
    41. Gong X, Schwartz PH, Linskey ME, Bota DA. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology. 2011 Mar 29; 76(13):1126-34. PMID: 21346220; PMCID: PMC3269770.
    42. Robie L, Alexandru D, Bota DA. The use of patient navigators to improve cancer care for Hispanic patients. Clin Med Insights Oncol. 2011 Feb 02; 5:1-7. PMID: 21339858; PMCID: PMC3040076.
    43. Kesari S, Bota DA. Fos-related antigen-1 (Fra-1) is a regulator of glioma cell malignant phenotype. Cancer Biol Ther. 2011 Feb 01; 11(3):307-10. PMID: 21242721.
      View in: PubMed
    44. Alexandru D, Van Horn DK, Bota DA. Secondary fibrosarcoma of the brain stem treated with cyclophosphamide and Imatinib. J Neurooncol. 2010 Aug; 99(1):123-8. PMID: 20043189; PMCID: PMC2895888.
    45. Bota DA, Dafer RM. Acute methotrexate neurotoxicity with choreiform movements and focal neurological deficits: a case report. South Med J. 2009 Oct; 102(10):1071-4. PMID: 19738521.
      View in: PubMed
    46. Bota RG, Sagduyu K, Filin EE, Bota DA, Munro S. Toward a better identification and treatment of schizophrenia prodrome. Bull Menninger Clin. 2008; 72(3):210-27. PMID: 18990056.
      View in: PubMed
    47. Bota DA, Desjardins A, Quinn JA, Affronti ML, Friedman HS. Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Ther Clin Risk Manag. 2007 Oct; 3(5):707-15. PMID: 18472995; PMCID: PMC2376068.
    48. Bota RG, Munro JS, Ricci WF, Bota DA. The dynamics of insight in the prodrome of schizophrenia. CNS Spectr. 2006 May; 11(5):355-62. PMID: 16641840.
      View in: PubMed
    49. Bota DA, Ngo JK, Davies KJ. Downregulation of the human Lon protease impairs mitochondrial structure and function and causes cell death. Free Radic Biol Med. 2005 Mar 01; 38(5):665-77. PMID: 15683722.
      View in: PubMed
    50. Bota DA, Van Remmen H, Davies KJ. Modulation of Lon protease activity and aconitase turnover during aging and oxidative stress. FEBS Lett. 2002 Dec 04; 532(1-2):103-6. PMID: 12459471.
      View in: PubMed
    51. Bota DA, Davies KJ. Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism. Nat Cell Biol. 2002 Sep; 4(9):674-80. PMID: 12198491.
      View in: PubMed
    Daniela's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _